Top

Published in:

01-05-2019 | Influenza Vaccination | Original Article

The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients—a 6-month follow-up prospective study

Authors: K. Lakota, K. Perdan-Pirkmajer, S. Sodin-Šemrl, S. Čučnik, V. Šubelj, K. Prosenc, K. Mrak Poljšak, M. Tomšič, A. Ambrožič, S. Praprotnik

Published in: Clinical Rheumatology | Issue 5/2019

Abstract

Introduction

Influenza may cause severe complications in patients with autoimmune inflammatory rheumatic disease (AIRD), to whom vaccinations are especially recommended. However, AIRD patients require cautious scrutiny of immunogenicity as they might exhibit poor antibody response to vaccination, especially when taking immunomodulatory medications.

Aim

The aim was to determine immunogenicity of seasonal and pandemic influenza vaccine in AIRD patients, its timeline/persistence, and influence of medications on immune response.

Methods

One hundred and thirty-seven AIRD and 54 healthy controls were vaccinated with trivalent seasonal influenza. After 3–5 weeks, 15 healthy controls and 93 AIRD were vaccinated with pandemic influenza vaccine, and 63 of patients were vaccinated a second time after 3–5 weeks. Sera were collected before vaccination, 18–90 days after each vaccination, and more than 180 days after the last vaccination. The immune response was measured using hemagglutination inhibition (HI) assay and IgG/IgA antibodies against influenza A/B with ELISA.

Results

Our findings indicate that following vaccination with seasonal influenza vaccine, seroprotection, seroresponse, and change in geometric mean titers (GMT) in AIRD patients was not compromised compared to healthy. Similarly, we report for pandemic influenza vaccination little added benefit of the second dose. We confirm lowest increase in HI titer in rituximab-treated AIRD compared to other medications. Vaccination largely tilts the balance from negative ELISA A IgG and IgA titers to positive titers in seasonal H1N1 seroresponsive AIRD patients and controls. A significant decrease in HI GMT and seroprotection was observed only in AIRD at > 180 days after vaccination highlighting an absent persistence of immunogenic response in AIRD patients. Due to high initial HI titers for influenza vaccine, we foresee their benefit in personalized medicine in the future.

Conclusion

Influenza vaccination is immunologically active for AIRD, with little value of the second dose of the pandemic vaccine and further scrutiny on persistence of immune response to vaccine in AIRD is needed.

Available only for authorised users

PublicHealthAgencyofCanada (2016) Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2015–2016.. http://www.phac-aspc.gc.ca/naci-ccni/assets/pdf/flu-2015-grippe-eng.pdf. Accessed 1st July 2016

van de Sandt CE, Kreijtz JH, Rimmelzwaan GF (2012) Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 4(9):1438–1476. https://doi.org/10.3390/v4091438 CrossRefPubMedPubMedCentral

Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber JT, D’Ancona F, Lévy-Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, O’Flanagan D (2014) Seasonal influenza immunisation in Europe. overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Eurosurveillance 19(16). https://doi.org/10.2807/1560-7917.ES2014.19.16.20780

Westra J, Rondaan C, van Assen S, Bijl M (2015) Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol 11(3):135–145. https://doi.org/10.1038/nrrheum.2014.206 CrossRefPubMed

Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, Sulli A, Valesini G, Sarzi-Puttini P (2008) Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol 26(1 Suppl 48):S67–S73PubMed

Blumentals WA, Arreglado A, Napalkov P, Toovey S (2012) Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. BMC Musculoskelet Disord 13:158. https://doi.org/10.1186/1471-2474-13-158 CrossRefPubMedPubMedCentral

van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Muller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M (2011) EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 70(3):414–422. https://doi.org/10.1136/ard.2010.137216 CrossRefPubMed

Harrison N, Poeppl W, Miksch M, Machold K, Kiener H, Aletaha D, Smolen JS, Forstner C, Burgmann H, Lagler H (2018) Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. Vaccine 36(32 Pt B):4875–4879. https://doi.org/10.1016/j.vaccine.2018.06.065 CrossRefPubMed

Perdan-Pirkmajer K, Thallinger GG, Snoj N, Cucnik S, Zigon P, Kveder T, Logar D, Praprotnik S, Tomsic M, Sodin-Semrl S, Ambrozic A (2012) Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 21(2):175–183. https://doi.org/10.1177/0961203311429817 CrossRefPubMed

10.

WHO (2009) Recommendations for influenza vaccine composition—Northern hemisphere: 2009–2010. http://www.who.int/influenza/vaccines/vaccinerecommendations1/en/index1.html. Accessed 15 Dec 2016

11.

WHO (2009) Pandemic influenza A (H1N1) 2009 virus vaccine—conclusions and recommendations from the October 2009 meeting of the immunization Strategic Advisory Group of Experts. http://www.who.int/csr/disease/swineflu/meetings/sage_oct_2009/en/. Accessed 16 Dec 2016

12.

Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS (2011) Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 204(12):1879–1885. https://doi.org/10.1093/infdis/jir661 CrossRefPubMed

13.

SanofiPasteur (2009) VAXIGRIP inactivated influenza vaccine trivalent types A and B (Split Virion). SanofiPasteur. https://www.vch.ca/media/residential_0910_product_monograph_vaxigrip.pdf. Accessed 16 Dec 2016

14.

EMA (2016) Pandemrix summary of product characteristics annex 1. http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121pdf Accessed 16 Dec 2016

15.

Noah DL, Hill H, Hines D, White EL, Wolff MC (2009) Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol: CVI 16(4):558–566. https://doi.org/10.1128/CVI.00368-08 CrossRefPubMed

16.

Zambon M (1997) Laboratory diagnosis of influenza. In: Nicholson K, Webster R, Hay A (eds) Influenza. Blackwell, Oxford, pp 123–156

17.

WHO (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Press. http://apps.who.int/iris/bitstream/10665/44518/1/9789241548090_eng.pdf. Accessed 27th July 2016

18.

FDA (2007) Guidance for industry: clincal data needed to support the licensure of seasonal inactivated influenza vaccines. 2007. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm. Accessed 25th July 2016

19.

EMA (2014) Guideline on influenza vaccines. Committee for Medicinal Products for Human Use. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170300.pdf. Accessed 25 July 2016

20.

Mori S, Ueki Y, Hirakata N, Oribe M, Hidaka T, Oishi K (2012) Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 71(12):2006–2010. https://doi.org/10.1136/annrheumdis-2012-201950 CrossRefPubMedPubMedCentral

21.

ECDC (2011) Influenza surveillance in Europe 2010–2011. ECDC. http://ecdc.europa.eu/en/publications/Publications/111209_SUR_Influenza_surveillance_Europe%20_2010_2012.pdf. Accessed 16 Dec 2016

22.

Liao Z, Tang H, Xu X, Liang Y, Xiong Y, Ni J (2016) Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis. PLoS One 11(2):e0147856. https://doi.org/10.1371/journal.pone.0147856 CrossRefPubMedPubMedCentral

23.

Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D (2010) The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 39(6):442–447. https://doi.org/10.1016/j.semarthrit.2008.12.002 CrossRefPubMed

24.

Kapetanovic MC, Kristensen LE, Saxne T, Aktas T, Morner A, Geborek P (2014) Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 16(1):R2. https://doi.org/10.1186/ar4427 CrossRefPubMedPubMedCentral

25.

Conti F, Rezai S, Valesini G (2008) Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 8(2):124–128. https://doi.org/10.1016/j.autrev.2008.07.007 CrossRefPubMed

26.

Meroni PL, Zavaglia D, Girmenia C (2018) Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol 36(2):317–328PubMed

27.

Stojanovich L (2006) Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Clin Dev Immunol 13(2–4):373–375. https://doi.org/10.1080/17402520600800820 CrossRefPubMedPubMedCentral

28.

Kobashigawa T, Nakajima A, Taniguchi A, Inoue E, Tanaka E, Momohara S, Yamanaka H (2013) Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 42(6):445–450. https://doi.org/10.3109/03009742.2013.788733 CrossRefPubMed

29.

Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, Teufel A (1994) Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol 21(7):1203–1206PubMed

30.

Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP (2008) The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 67(5):713–716. https://doi.org/10.1136/ard.2007.077552 CrossRefPubMed

31.

Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK (2014) Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol 41(4):648–657. https://doi.org/10.3899/jrheum.130945 CrossRefPubMed

32.

Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podesta E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Lagana B, DA R (2010) Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 134(2):113–120. https://doi.org/10.1016/j.clim.2009.09.014 CrossRefPubMed

33.

Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, Arad U, Brill A, Paran D, Levartovsky D, Wigler I, Caspi D, Mandelboim M (2011) Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 63(7):1062–1067. https://doi.org/10.1002/acr.20465 CrossRef

34.

Saad CG, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, Moraes JC, Ribeiro AC, Viana VS, Pasoto SG, Carvalho JF, Franca IL, Guedes LK, Shinjo SK, Sampaio-Barros PD, Caleiro MT, Goncalves CR, Fuller R, Levy-Neto M, Timenetsky Mdo C, Precioso AR, Bonfa E (2011) Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 70(6):1068–1073. https://doi.org/10.1136/ard.2011.150250 CrossRefPubMed

35.

Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay-Barbe K, Grillet S, Seebach JD, Kaiser L, Wunderli W, Guerne PA, Siegrist CA, Group HNS (2011) Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 63(6):1486–1496. https://doi.org/10.1002/art.30325 CrossRefPubMed

36.

Iwamoto M, Homma S, Onishi S, Kamata Y, Nagatani K, Yamagata Z, Minota S (2012) Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 32(11):3691–3694. https://doi.org/10.1007/s00296-011-2118-1 CrossRefPubMed

37.

Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE (2013) Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33(2):388–396. https://doi.org/10.1007/s10875-012-9813-x CrossRefPubMed

38.

van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75–81. https://doi.org/10.1002/art.25033 CrossRefPubMed

39.

Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 65(2):191–194. https://doi.org/10.1136/ard.2005.036434 CrossRefPubMed

40.

McMahan ZH, Bingham CO 3rd (2014) Effects of biological and non-biological immunomodulatory therapies on the immunogenicity of vaccines in patients with rheumatic diseases. Arthritis Res Ther 16(6):506. https://doi.org/10.1186/s13075-014-0506-0 CrossRefPubMedPubMedCentral

41.

Miossi R, Fuller R, Moraes JC, Ribeiro AC, Saad CG, Aikawa NE, Miraglia JL, Ishida MA, Bonfa E, Caleiro MT (2013) Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics 68(2):129–134CrossRefPubMedPubMedCentral

42.

Montomoli E, Capecchi B, Hoschler K (2011) Correlates of protection against influenza. Birkhauser Adv Infec:199–222. https://doi.org/10.1007/978-3-0346-0279-2_9

43.

Jain VK, Bhashini N, Balajee LK, Sistla S, Parija SC, Negi VS (2017) Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis. Indian J Med Res 145(4):464–470. https://doi.org/10.4103/ijmr.IJMR_920_15

44.

Okamoto S, Matsuoka S, Takenaka N, Haredy AM, Tanimoto T, Gomi Y, Ishikawa T, Akagi T, Akashi M, Okuno Y, Mori Y, Yamanishi K (2012) Intranasal immunization with a formalin-inactivated human influenza A virus whole-virion vaccine alone and intranasal immunization with a split-virion vaccine with mucosal adjuvants show similar levels of cross-protection. Clin Vaccine Immunol: CVI 19(7):979–990. https://doi.org/10.1128/CVI.00016-12 CrossRefPubMed

45.

Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN (2015) Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines. Clin Vaccine Immunol: CVI 22(7):679–687. https://doi.org/10.1128/CVI.00149-15 CrossRefPubMed

46.

Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, Nguyen-Van-Tam JS, Abhishek A (2018) Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study. Rheumatology 57(10):1726–1734. https://doi.org/10.1093/rheumatology/key156 CrossRefPubMed

47.

Subelj V, Prosenc K, Socan M (2012) Seroprevalence study of antibodies against influenza A (H1N1) 2009 virus after the second pandemic wave in Slovenia. Wien Klin Wochenschr 124(5–6):177–180. https://doi.org/10.1007/s00508-012-0126-0 CrossRefPubMed

Title: The immunogenicity of seasonal and pandemic influenza vaccination in autoimmune inflammatory rheumatic patients—a 6-month follow-up prospective study
Authors: K. Lakota
K. Perdan-Pirkmajer
S. Sodin-Šemrl
S. Čučnik
V. Šubelj
K. Prosenc
K. Mrak Poljšak
M. Tomšič
A. Ambrožič
S. Praprotnik
Publication date: 01-05-2019
Publisher: Springer London
Keywords: Influenza Vaccination
Vaccination
Rituximab
Influenza
Rituximab
Published in: Clinical Rheumatology / Issue 5/2019
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-019-04439-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2019

A survey of traditional Chinese medicine use among rheumatoid arthritis patients: a claims data–based cohort study

First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment

Plasma let-7i, miR-16, and miR-221 levels as candidate biomarkers for the assessment of ankylosing spondylitis in Mexican patients naïve to anti-TNF therapy

Venous vessel wall thickness in lower extremity is increased in male patients with Behcet’s disease

Functional implications of single nucleotide polymorphisms rs662 and rs854860 on the antioxidative activity of paraoxonase1 (PON1) in patients with rheumatoid arthritis

Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage